Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.

Lung cancer (Amsterdam, Netherlands) - 1 Oct 2023

Seker-Cin Huriye, Tay Timothy Kwang Yong, Kazdal Daniel, Kluck Klaus, Ball Markus, Neumann Olaf, Winter Hauke, Herth Felix, Heußel Claus-Peter, Savai Rajkumar, Schirmacher Peter, Thomas Michael, Budczies Jan, Allgäuer Michael, Christopoulos Petros, Stenzinger Albrecht, Volckmar Anna-Lena

Abstract excerpt

OBJECTIVES: Molecular diagnosis for targeted therapies has been improved significantly in non-small-cell lung cancer (NSCLC) patients in recent years. Here we report on the prevalence of rare fusions in NSCLC and dissect their genomic architecture and potential clinical implications. MATERIALS AND METHODS: Overall, n = 5554 NSCLC patients underwent next-generation sequencing (NGS) for combined detection of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 37586177
DOI: 10.1016/j.lungcan.2023.107317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.PMID 37586177Read ↗

Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLCSemantic proximity Read ↗

Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.Semantic proximity Read ↗

Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implicationsSemantic proximity Read ↗

Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.Semantic proximity Read ↗

Unveiling the Uncommon: Targeting Rare MET Fusions in NSCLC: A Comprehensive ReviewSemantic proximity Read ↗

Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLCSemantic proximity Read ↗

Rare molecular subtypes of lung cancer.Semantic proximity Read ↗

Oncogenic gene fusions in cancer: from biology to therapySemantic proximity Read ↗

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusionsSemantic proximity Read ↗

Clinically relevant fusion oncogenes: detection and practical implicationsSemantic proximity Read ↗

Detection of gene fusions using targeted next-generation sequencing: a comparative evaluationSemantic proximity Read ↗

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical ApplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.